Corvus Pharmaceuticals, Inc. Cash Flow Statement
CRVS / Health Care|11 years of annual SEC 10-K data (FY2014-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 11 fiscal years. All figures from audited SEC 10-K filings.
Corvus Pharmaceuticals, Inc. used $25M in operating cash flow in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$62.3M | -$27.0M | -$41.3M | -$43.2M | -$6.0M | -$46.7M | -$46.9M | -$55.7M | -$36.4M | -$31.3M | -$161.0K |
| Depreciation & Amortization | $85.0K | $151.0K | $367.0K | $460.0K | $632.0K | $743.0K | $847.0K | $842.0K | $594.0K | $148.0K | - |
| Operating Cash Flow | -$25.4M | -$23.9M | -$27.0M | -$36.7M | -$34.8M | -$37.3M | -$41.0M | -$46.2M | -$27.9M | -$11.3M | -$96.0K |
| Capital Expenditures | - | $34.0K | $269.0K | $5.0K | $76.0K | $25.0K | $355.0K | $266.0K | $2.2M | $1.7M | - |
| Free Cash Flow | - | -$24.0M | -$27.3M | -$36.7M | -$34.9M | -$37.3M | -$41.3M | -$46.5M | -$30.1M | -$13.1M | - |